State-of-the-art human gene therapy: Part II. gene therapy strategies and clinical applications

Discovery Medicine

Volumn 18, Issue 98, 2014, Pages 151-161

  Wang, Dan ^a   Gao, Guangping ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 9; CHEMOKINE RECEPTOR CXCR5; HYPERLIPOPROTEINEMIA TYPE 1; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; LIPOPROTEIN LIPASE; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SURVIVAL MOTOR NEURON PROTEIN 1; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DNA END JOINING REPAIR; DUCHENNE MUSCULAR DYSTROPHY; GENE; GENE ADDITION; GENE DELIVERY SYSTEM; GENE DISRUPTION; GENE EDITING; GENE EXPRESSION REGULATION; GENE REPLACEMENT THERAPY; GENE THERAPY; HEART FAILURE; HEMOPHILIA B; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; INFECTION; LEBER CONGENITAL AMAUROSIS; LIPOPROTEIN LIPASE GENE; MONOGENIC DISORDER; MULTIFACTORIAL GENETIC DISORDER; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTRANSDUCTION; RETINAL PIGMENT EPITHELIUM SPECIFIC PROTEIN 65 KDA GENE; RNA INTERFERENCE; CLINICAL TRIAL (TOPIC); GENE SILENCING; GENETIC DISEASES, INBORN; GENETIC RECOMBINATION; GENETICS; NEOPLASMS; PROCEDURES; RNA EDITING; RNA SPLICING; TARGETED GENE REPAIR; TRENDS;

CLINICAL TRIALS AS TOPIC; DNA END-JOINING REPAIR; GENE KNOCKDOWN TECHNIQUES; GENETIC DISEASES, INBORN; GENETIC THERAPY; HEART FAILURE; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RECOMBINATION, GENETIC; RNA EDITING; RNA INTERFERENCE; RNA SPLICING; TARGETED GENE REPAIR;

EID: 84940534837     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Aiuti A, Cattaneo F, Galimberti S, BenninghoffU, Cassani B, Callegaro L, Scaramuzza S, AndolfiG, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360(5):447-458, 2009.
2. Andtbacka RH, Ross MI, Delman K, Noyes D, Zager JS, Hsueh E, Ollila DW, Amatruda T, Chen L, Kaufman H. Responses of Injected and Uninjected Lesions to Intralesional Talimogene Laherparepvec (T-VEC) in the OPTiM Study and the Contribution of Surgery to Response. Society of Surgical Oncology Cancer Symposium. Phoenix, Arizona, USA, 2014.
3. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358(21):2231-2239, 2008.
4. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 31(7):647-652, 2013.
5. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481(7379):81-84, 2012.
6. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, Mccague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4(120):120ra115, 2012.
7. BiffiA, Aubourg P, Cartier N. Gene therapy for leukodystrophies. Hum Mol Genet 20(R1):R42-R53, 2011.
8. Borel F, Kay MA, Mueller C. Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference. Mol Ther 22(4):692-701, 2014.
9. Boudreau RL, Garwick-Coppens SE, Liu J, Wallace LM, Harper SQ. Rapid Cloning and Validation of MicroRNA Shuttle Vectors: A Practical Guide, In: RNA Interference Techniques. SQ Harper (ed.). pp19-37. Springer Science+Business Media, LLC, Berlin, Germany, 2011.
10. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17(1):169-175, 2009.
11. Bradshaw AC, Baker AH. Gene therapy for cardiovascular disease: perspectives and potential. Vascul Pharmacol 58(3):174-181, 2013.
12. Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an empty suit? Lancet Oncol 14(11):e447-456, 2013.
13. Cannon P, June C. Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS 6(1):74-79, 2011.
14. Carbonaro DA, Zhang L, Jin X, Montiel-Equihua C, Geiger S, Carmo M, Cooper A, Fairbanks L, Kaufman ML, Sebire NJ, Hollis RP, Blundell MP, Senadheera S, Fu PY, Sahaghian A, Chan RY, Wang X, Cornetta K, Thrasher AJ, Kohn DB, et al. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther 22(3):607-622, 2014.
15. Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Komaromy AM, Hauswirth WW, Aguirre GD. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A 110(6):E517-E525, 2013.
16. Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK, Tang T. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538(2):217-227, 2014.
17. Fellmann C, Lowe SW. Stable RNA interference rules for silencing. Nat Cell Biol 16(1):10-18, 2014.
18. Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol 5:82, 2014a.
19. Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D, Methot J, Petry H, Gaudet D. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 25(3):180-188, 2014b.
20. Gaj T, Gersbach CA, Barbas CF, 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397-405, 2013.
21. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Zhang F, Adams S, Bjorkegren E, Bayford J, Brown L, Davies EG, Veys P, Fairbanks L, Bordon V, Petropoulou T, Kinnon C, Thrasher AJ. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 3(97):97ra80, 2011.
22. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, Tremblay K, De Wal J, Twisk J, Van Den Bulk N, Sier-Ferreira V, Van Deventer S. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20(4):361-369, 2013.
23. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 23(4):310-320, 2012.
24. Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 vectors for gene therapy. Methods Mol Biol 1144:63-79, 2014.
25. Goyenvalle A, Babbs A, Wright J, Wilkins V, Powell D, Garcia L, Davies KE. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet 21(11):2559-2571, 2012a.
26. Goyenvalle A, Davies KE. Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy. Methods Mol Biol 709:179-196, 2011.
27. Goyenvalle A, Wright J, Babbs A, Wilkins V, Garcia L, Davies KE. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther 20(6):1212-1221, 2012b.
28. Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 22(R1):R52-R58, 2013.
29. Guilinger JP, Pattanayak V, Reyon D, Tsai SQ, Sander JD, Joung JK, Liu DR. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods 11(4):429-435, 2014.
30. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debre M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363(4):355-364, 2010.
31. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19(10):979-990, 2008.
32. High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia 20(Suppl 4):43-49, 2014.
33. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 5(4):e73, 2007.
34. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, Peden MC, Aleman TS, Boye SL, Sumaroka A, Conlon TJ, Calcedo R, Pang JJ, Erger KE, Olivares MB, Mullins CL, Swider M, Kaushal S, Feuer WJ, Iannaccone A, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130(1):9-24, 2012.
35. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124(3):304-313, 2011.
36. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15(8):901-906, 2009.
37. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49-55, 2013.
38. Kiser PD, Palczewski K. Membrane-binding and enzymatic properties of RPE65. Prog Retin Eye Res 29(5):428-442, 2010.
39. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10(5):267-276, 2013.
40. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20):4099-4102, 2010.
41. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circulation Res 110(12):1646-1660, 2012.
42. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela XM, Sharma R, Ivanciu L, Murphy SL, Finn JD, Khazi FR, Zhou S, Paschon DE, Rebar EJ, Bushman FD, Gregory PD, Holmes MC, High KA. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475(7355):217-221, 2011.
43. Li M, Suzuki K, Kim NY, Liu GH, Izpisua Belmonte JC. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 289(8):4594-4599, 2014.
44. Lisa Li H, Nakano T, Hotta A. Genetic correction using engineered nucleases for gene therapy applications. Dev Growth Differ 56(1):63-77, 2014.
45. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther 12(6):1013-1022, 2005.
46. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr, Mingozzi F, Bennicelli J, BanfiS, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'osso L, Hertle R, Ma JX, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358(21):2240-2248, 2008.
47. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 10(10):957-963, 2013.
48. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1):23-36, 2013.
49. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES, High KA. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114(10):2077-2086, 2009.
50. Mitrpant C, Porensky P, Zhou H, Price L, Muntoni F, Fletcher S, Wilton SD, Burghes AH. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One 8(4):e62114, 2013.
51. Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD 10(Suppl 1):44-49, 2013.
52. Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, Zamore PD, Flotte TR. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther 20(3):590-600, 2012.
53. Nienhuis AW. Development of gene therapy for blood disorders: an update. Blood 122(9):1556-1564, 2013.
54. Palpant NJ, Dudzinski D. Zinc finger nucleases: looking toward translation. Gene Ther 20(2):121-127, 2013.
55. Patel N, Reiss U, DavidoffAM, Nathwani AC. Progress towards gene therapy for haemophilia B. Int J Hematol 99(4):372-376, 2014.
56. Petersen-Jones SM, Annear MJ, Bartoe JT, Mowat FM, Barker SE, Smith AJ, Bainbridge JW, Ali RR. Gene augmentation trials using the Rpe65-deficient dog: contributions towards development and refinement of human clinical trials. Adv Exp Med Biol 723:177-182, 2012.
57. Pfister EL, Zamore PD. Huntington's disease: silencing a brutal killer. Exp Neurol 220(2):226-229, 2009.
58. Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci 36:467-488, 2013.
59. San Sebastian W, Samaranch L, Kells AP, Forsayeth J, Bankiewicz KS. Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics 10(3):498-510, 2013.
60. Sikkel MB, Hayward C, Macleod KT, Harding SE, Lyon AR. SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. Br J Pharmacol 171(1):38-54, 2014.
61. Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC. Progress in gene therapy for neurological disorders. Nat Rev Neurol 9(5):277-291, 2013.
62. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A 100(7):4114-4119, 2003.
63. Stein L, Roy K, Lei L, Kaushal S. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis. Expert Opin Biol Ther 11(3):429-439, 2011.
64. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross C, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28(12):2303-2304, 2008.
65. Wang D, Gao G. State-of-the-art human gene therapy: Part I. Gene delivery technologies. Discov Med 18(97):67-77, 2014.
66. Wang D, Zhong L, Nahid MA, Gao G. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11(3):345-364, 2014a.
67. Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q, Guo Y, Brown RH, Jr., Gao G, Xu Z. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 23(3):668-681, 2014b.
68. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 20(10):1831-1832, 2012.
69. Zhang L, Thrasher AJ, Gaspar HB. Current progress on gene therapy for primary immunodeficiencies. Gene Ther 20(10):963-969, 2013.
70. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circulation Res 114(1):101-108, 2014.